Massmutual Trust Co. FSB ADV Acquires 222 Shares of Moderna, Inc. (NASDAQ:MRNA)

Massmutual Trust Co. FSB ADV grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 38.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 793 shares of the company’s stock after purchasing an additional 222 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Moderna were worth $94,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Ogorek Anthony Joseph NY ADV bought a new stake in Moderna during the 4th quarter worth $27,000. Cedar Wealth Management LLC boosted its stake in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after purchasing an additional 90 shares in the last quarter. Arlington Trust Co LLC grew its holdings in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after purchasing an additional 290 shares during the last quarter. Westside Investment Management Inc. acquired a new position in shares of Moderna in the first quarter valued at approximately $32,000. Finally, Rise Advisors LLC raised its holdings in Moderna by 953.3% in the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock valued at $34,000 after buying an additional 286 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Down 1.7 %

NASDAQ MRNA traded down $1.45 on Tuesday, hitting $82.30. 5,103,636 shares of the company were exchanged, compared to its average volume of 4,161,834. The company has a current ratio of 4.09, a quick ratio of 3.91 and a debt-to-equity ratio of 0.05. The company has a market cap of $31.54 billion, a PE ratio of -5.19 and a beta of 1.67. The stock has a fifty day moving average of $129.81 and a 200-day moving average of $115.22. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the prior year, the firm earned ($3.62) EPS. The business’s revenue was down 29.9% on a year-over-year basis. As a group, analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current year.

Insider Activity

In other news, Director Noubar Afeyan sold 202,832 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the completion of the sale, the director now directly owns 1,528,557 shares of the company’s stock, valued at $226,746,145.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Noubar Afeyan sold 202,832 shares of Moderna stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $148.34, for a total transaction of $30,088,098.88. Following the transaction, the director now owns 1,528,557 shares of the company’s stock, valued at $226,746,145.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 255 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now directly owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The disclosure for this sale can be found here. Insiders sold a total of 396,239 shares of company stock worth $55,563,937 over the last quarter. 15.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Barclays reduced their target price on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating on the stock in a report on Friday. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, June 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Thursday, August 1st. Royal Bank of Canada lowered Moderna from an “outperform” rating to a “sector perform” rating and reduced their price target for the company from $125.00 to $90.00 in a research report on Monday. Finally, Piper Sandler restated an “overweight” rating and set a $157.00 price objective (down from $214.00) on shares of Moderna in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $122.79.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.